Publication
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugElacestrantcivic_curation1.00
- geneESR1civic_curation1.00
- variantESR1 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (13)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35584336
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ESR1 Mutation1 | ||||||||
| Elacestrant | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11443In a phase 3 trial (NCT03778931), the selective ER-degrader elacestrant was shown to increase progression free survival (PFS) in both ESR1 mutant and ESR1 wild type, ER-positive, HER2-negative breast … (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 D538G1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID12219In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 E380Q1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12224In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 L469V1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12225In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 L536H1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12226In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 L536P1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12227In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 L536Q1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12229In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 L536R1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12228In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 S463P1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12230In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 Y537C1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12222In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 Y537D1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12223In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 Y537N1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12221In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |
| ESR1 Y537S1 | ||||||||
| Elacestrant | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12220In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC | civic |